Clinical catalysts to boost awareness
Bone Therapeutics SA (BR:BOTHE) develops therapies to prevent and treat fractures by addressing underlying problems in bone regeneration. In November, the company’s allogeneic cell therapy product, ALLOB, received Orphan Drug Designation (ODD) from the EMA and the US FDA for the treatment of the genetic bone disorder osteogenesis imperfecta. Over the next two years, we expect frequent clinical development updates from Phase II and Phase III trials to boost awareness and interest in Bone Therapeutics’ cell therapy technology and investment case.
Frequent clinical updates provide catalysts
Bone Therapeutics has ongoing clinical trials in five indications: delayed-union fractures, non-union fractures, spine fusion, osteonecrosis and osteoporosis. Bone’s most advanced indications are for PREOB, an autologous cell therapy product in non-union fractures and in osteonecrosis, where the company is running Phase III trials and awaiting interim follow-up data. In Q315, Bone initiated its Phase IIa trial for the minimally invasive treatment of failed spinal fusion procedures with ALLOB, its allogeneic product. This trial is the first involving administration of a bone cell therapy product without open surgery. Bone expects to report additional safety results from its trials in spinal fusion procedures over the next few months.
To Read the Entire Report Please Click on the pdf File Below